Sillajen Inc. (215600)
Market Open
11 Aug, 06:30
KRX SM KRX SM Primary ₩
2,325. 00
+50
+2.1978%
₩
425.44B Market Cap
- P/E Ratio
- Div Yield
52,944 Volume
- Eps
₩ 2,275
Previous Close Want to track 215600 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
215600 trading today higher at ₩2,325, an increase of 2.1978% from yesterday's close, completing a monthly increase of 0.432% or ₩10. Over the past 12 months, 215600 stock lost -33.5714%.
215600 is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -14.1818%, based on the last three reports.
Sillajen Inc. has completed 1 stock splits, with the recent split occurring on May 09, 2024.
The company's stock is traded on one exchange.
Sillajen Inc. (215600) FAQ
What is the stock price today?
The current price is ₩2,325.00.
On which exchange is it traded?
Sillajen Inc. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 215600.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 425.44B.
Has Sillajen Inc. ever had a stock split?
Sillajen Inc. had 1 splits and the recent split was on May 09, 2024.
Sillajen Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Jaekyung Kim CEO | KRX SM Exchange | KR7215600008 ISIN |
| KR Country | 37 Employees | - Last Dividend | 9 May 2024 Last Split | - IPO Date |
Overview
SillaJen, Inc., founded in 2006 and headquartered in Seoul, South Korea, focuses on the development and commercialization of innovative oncolytic immunotherapy products. The company aims to provide new therapeutic options for cancer patients, particularly those battling advanced liver cancer, utilizing its expertise in biotechnology to engineer viruses that selectively target and destroy cancer cells while sparing healthy ones. SillaJen's commitment to advancing cancer treatment options showcases its role as a key player in the biopharmaceutical industry.
Products and Services
- Pexa-Vec: SillaJen's flagship product, primarily aimed at treating advanced liver cancer. Pexa-Vec is an oncolytic virus therapy designed to selectively kill cancer cells and stimulate the patient's immune response against tumors.
- BAL0891: This product is a dual inhibitor targeting TTK and PLK proteins, which are involved in cell division. By inhibiting these proteins, BAL0891 aims to halt the proliferation of cancer cells, offering a potential therapeutic avenue for various cancers.
- SJ-600: Developed to enhance the intravenous administration efficiency of anticancer viruses, SJ-600 represents SillaJen's effort to improve the delivery mechanisms of viral therapies, potentially increasing their effectiveness and patient outcomes.
- JX-970: A specialized treatment designed to target tumor tissues directly. JX-970 works as a refined oncolytic virus therapy, emphasizing SillaJen’s focus on precision medicine in oncology.
- JX-900: A series of modified vaccinia vaccines, JX-900 demonstrates SillaJen’s ongoing pursuit of innovative vaccine technology to combat cancer. These vaccines are engineered to stimulate the immune system’s response to tumor cells, providing an additional strategy in the fight against cancer.
Contact Information
Address: 109, Sogong-ro
Phone: 82 2 368 2600
Website: https://www.sillajen.com
